
==== Front
Mol Psychiatry
Mol Psychiatry
Molecular Psychiatry
1359-4184
1476-5578
Nature Publishing Group UK London

38491343
2457
10.1038/s41380-024-02457-0
Article
Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis
http://orcid.org/0000-0001-5125-0868
Warren Tracy L. 123
Tubbs Justin D. 4567
http://orcid.org/0000-0002-6160-3927
Lesh Tyler A. 2
Corona Mylena B. 123
Pakzad Sarvenaz S. 2
Albuquerque Marina D. 2
Singh Praveena 2
http://orcid.org/0000-0002-3925-4871
Zarubin Vanessa 28
Morse Sarah J. 1239
Sham Pak Chung pcsham@hku.hk

41011
Carter Cameron S. cscarte1@hs.uci.edu

212
http://orcid.org/0000-0003-4259-7514
Nord Alex S. asnord@ucdavis.edu

123
1 grid.27860.3b 0000 0004 1936 9684 Department of Neurobiology, Physiology and Behavior, University of California, Davis, CA USA
2 grid.27860.3b 0000 0004 1936 9684 Department of Psychiatry and Behavioral Sciences, University of California, Davis, CA USA
3 grid.27860.3b 0000 0004 1936 9684 Center for Neuroscience, University of California, Davis, CA USA
4 https://ror.org/02zhqgq86 grid.194645.b 0000 0001 2174 2757 Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR
5 https://ror.org/002pd6e78 grid.32224.35 0000 0004 0386 9924 Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA USA
6 grid.38142.3c 000000041936754X Department of Psychiatry, Harvard Medical School, Boston, MA USA
7 grid.66859.34 0000 0004 0546 1623 Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA USA
8 https://ror.org/000e0be47 grid.16753.36 0000 0001 2299 3507 Department of Psychology, Northwestern University, Evanston, IL USA
9 https://ror.org/01yc7t268 grid.4367.6 0000 0004 1936 9350 Department of Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, MO USA
10 https://ror.org/02zhqgq86 grid.194645.b 0000 0001 2174 2757 Centre for PanorOmic Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR
11 grid.194645.b 0000000121742757 State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR
12 grid.266093.8 0000 0001 0668 7243 Department of Psychiatry and Human Behavior, University of California, Irvine, CA USA
15 3 2024
15 3 2024
2024
29 8 23892398
12 4 2023
19 1 2024
24 1 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
A primary goal of psychiatry is to better understand the pathways that link genetic risk to psychiatric symptoms. Here, we tested association of diagnosis and endophenotypes with overall and neurotransmitter pathway-specific polygenic risk in patients with early-stage psychosis. Subjects included 205 demographically diverse cases with a psychotic disorder who underwent comprehensive psychiatric and neurological phenotyping and 115 matched controls. Following genotyping, we calculated polygenic scores (PGSs) for schizophrenia (SZ) and bipolar disorder (BP) using Psychiatric Genomics Consortium GWAS summary statistics. To test if overall genetic risk can be partitioned into affected neurotransmitter pathways, we calculated pathway PGSs (pPGSs) for SZ risk affecting each of four major neurotransmitter systems: glutamate, GABA, dopamine, and serotonin. Psychosis subjects had elevated SZ PGS versus controls; cases with SZ or BP diagnoses had stronger SZ or BP risk, respectively. There was no significant association within psychosis cases between individual symptom measures and overall PGS. However, neurotransmitter-specific pPGSs were moderately associated with specific endophenotypes; notably, glutamate was associated with SZ diagnosis and with deficits in cognitive control during task-based fMRI, while dopamine was associated with global functioning. Finally, unbiased endophenotype-driven clustering identified three diagnostically mixed case groups that separated on primary deficits of positive symptoms, negative symptoms, global functioning, and cognitive control. All clusters showed strong genome-wide risk. Cluster 2, characterized by deficits in cognitive control and negative symptoms, additionally showed specific risk concentrated in glutamatergic and GABAergic pathways. Due to the intensive characterization of our subjects, the present study was limited to a relatively small cohort. As such, results should be followed up with additional research at the population and mechanism level. Our study suggests pathway-based PGS analysis may be a powerful path forward to study genetic mechanisms driving psychiatric endophenotypes.

Subject terms

Genetics
Neuroscience
Psychology
Schizophrenia
Bipolar disorder
https://doi.org/10.13039/100007707 UC | University of California, Davis (UC Davis) UC Davis-HKU Collaboration Grant UC Davis-HKU Collaboration Grant UC Davis-HKU Collaboration Grant Sham Pak Chung Carter Cameron S. Nord Alex S. https://doi.org/10.13039/100000025 U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) T32MH112507 F31MH129135 R01MH059883 Warren Tracy L. Carter Cameron S. issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Psychosis-spectrum disorders, including schizophrenia (SZ), schizoaffective disorder (SA), and bipolar disorder (BP), affect 0.5–2.3% of people worldwide [1–5]. Evidence suggests shared etiology for these disorders, supported by family studies and genome-wide association studies (GWASs) showing high interheritability and shared genomic risk [6–8]. Given symptom heterogeneity across the psychosis spectrum, a deeper understanding of the biology underlying specific symptoms may drive psychiatry towards improved patient outcomes using stratified medicine.

One approach toward revealing shared neurobiology is identifying transdiagnostic endophenotypes. Recently, the Bipolar & Schizophrenia Network for Intermediate Phenotypes (B-SNIP) Consortium identified three biotypes of psychotic disorders using neuropsychiatric markers, agnostic to diagnoses [9], that were primarily characterized by differences in cognitive control and sensorimotor reactivity. As knowledge of biology underlying symptom heterogeneity expands, reclassifying psychosis patients using biologically grounded phenotypes may allow for more effective, targeted interventions.

Identification of causal and clinically informative genetic components of psychotic disorders has been aided by large-scale GWASs and estimation of overall genetic risk using polygenic scores (PGSs). While large cohorts were initially required to develop PGSs, once defined, research leveraging PGSs in cohorts with phenotyping that extends beyond diagnosis is revealing how genetic burden is associated with specific symptomatology. For example, recent efforts have found associations between SZ PGS and treatment response [10] as well as neurological and cognitive measures [11, 12]. Such uses of PGS enable study of genetic burden in small cohorts that have been characterized at a level not feasible at the scale required for GWASs focused on the discovery of new risk loci.

While PGS is a useful metric of genetic risk, it fails to assign burden into relevant biological pathways and elucidate mechanisms underlying symptoms. A novel approach to overcome this is pathway-specific PGS (pPGS), which partitions variants into those contained only in genes of a given function or pathway [13]. By assigning burden into pathways, it is possible to test how specific processes contribute to phenotype. This has been used to associate miR-137 pPGS with SZ risk [14] and neurological markers [15, 16]. Another recent implementation identified SZ and BP subjects with risk in pathways targetable by available pharmaceuticals, showing the utility of pPGS in targeted medicine [17]. Among pathways relevant to psychosis, glutamate [18–23], GABA [19–24], dopamine [23, 25–28], and serotonin [23, 28, 29] systems have been strongly associated with psychotic disorders and therapeutics.

There is a major opportunity to use pPGS to identify pathway contributions to psychosis symptoms. Here, we investigated the relationship of overall and neurotransmitter-associated PGS to psychotic disorder presentation at the diagnostic and endophenotypic level. We estimated overall and pathway-level PGS for a diverse cohort recruited from California following a first psychotic episode, and tested association between genetic burden, diagnosis, and clinical and neuroimaging endophenotypes. In a cohort of 205 subjects with psychotic disorders versus 115 controls, we found that overall and pathway PGSs were elevated in cases, pPGS was moderately associated with specific endophenotypes, and unbiased clustering on phenotypes showed associations with pPGS and treatment response. Our results demonstrate the power of pPGS to test the relationships between affected biological pathways and transdiagnostic phenotypes.

Methods

Study participants

Psychosis subjects were all outpatients within two years of their first psychotic episode. Subjects were selected from an ongoing psychosis research cohort, which includes 196 first-episode SZ-spectrum patients, 53 patients with first-episode BP with psychotic features, and 135 controls aged 12–38. After all quality control (QC), 118 SZ, 39 SA, 48 BP, and 115 controls were included for this study from an ongoing early psychosis research cohort. The study was approved by the University of California, Davis, Institutional Review Board and all subjects gave written consent and were paid for their participation.

Psychiatric and neuroimaging phenotyping

All participants were assessed using the Structured Clinical Interview for the DSM-IV-TR (SCID I/P) [30]. Clinical interviews were conducted by clinicians with masters or doctoral degrees trained to high reliability (kappa > 0.70; range = 0.70–1.0). All patients were followed longitudinally and diagnoses were confirmed 6 months after ascertainment. Exclusion criteria for all groups included: Wechsler Abbreviated Scale of Intelligence (WASI) IQ score below 70, alcohol or drug dependence or abuse within 3 months before testing, positive urine toxicology screen for illicit drugs, prior head trauma worse than a Grade I concussion, or contraindication to MRI scanning. Control subjects were excluded for the following additional criteria: any lifetime diagnosis of an Axis I or Axis II disorder or any first-degree relatives with a psychotic disorder. Before testing, a detailed description of the study was provided and written informed consent obtained.

Subjects were evaluated on the Global Assessment of Functioning (GAF) [31], Global Social Functioning scale (GSF) [32], Global Role Functioning scale (GRF) [33], Young Mania Rating Scale (YMRS) [34], Scale for the Assessment of Positive Symptoms (SAPS) [35], Scale for the Assessment of Negative Symptoms (SANS) [35], and Brief Psychiatric Rating Scale (BPRS) [36]. Reality distortion, poverty symptoms, and disorganization scores were defined from the BPRS, SAPS, and SANS [37]. Treatment response was defined as >20% decrease in BPRS from baseline [38].

The GSF and GRF were measured at multiple time points; for each scale, we computed an average of the highest and lowest values measured for each subject during the past year and proceeded with these values for subsequent analyses. Finally, we removed item #8 (“Content”) from scores for the YMRS, as this question asks specifically about positive psychotic symptoms and can skew YMRS scores for subjects with schizophrenia. As such, scores on the YMRS used in these analyses more directly represent mania-specific symptoms. At baseline, all patients had BPRS scores ≥5 to offer sufficient resolution to detect a 20% improvement in score at follow-up. For treatment response calculation, BPRS was rescaled to a lowest score of zero (i.e. score of 24 = score of 0) [39].

Behavioral and neuroimaging methods are described previously [40]. Consequently, we present these methods in a condensed form. The AX-Continuous Performance Task (AX-CPT) [41] was performed during fMRI. In short, the task requires participants to respond to a series of cue and probe letters and correctly identify the target pair (“AX” trials) while correctly rejecting other pairs. The frequency manipulation of trial types creates a prepotent tendency to make a target response when the “X” probe letter is presented. Consequently when a non-A cue is presented and followed by an X (i.e. “BX” trials) the participant must engage proactive control to retain the goal, keep the incorrect cue in mind, and correctly reject the trial at the probe phase. Participants were excluded if performance did not meet a minimal threshold [42]. The primary behavioral measure used for this study is d’-context, which represents a contrast of AX hits versus BX false alarms.

Functional Blood Oxygenation Level Dependent (BOLD) data were acquired using a 1.5 T GE Signa and 3.0 T Siemens TimTrio. Two regions of interest were defined a priori and comprised CueB versus CueA contrast, reflecting high versus low cognitive control-related activity. Specifically, bilateral dorsolateral prefrontal cortex (DLPFC) and bilateral superior parietal cortex (SPC) were defined as 5 mm radius spheres based on coordinates from two independent datasets [43, 44]. All fMRI data were preprocessed using SPM8 (Wellcome Dept. of Imaging Neuroscience, London) and included slice timing correction, realignment, normalization to the Montreal Neurological Institute (MNI) template, and smoothing with an 8 mm FWHM Gaussian kernel. Individual runs were excluded when framewise displacement measures of movement exceeded 0.45 mm (calculated with https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLMotionOutliers) and whole subjects were excluded if more than half of their data exceeded this threshold. All trial types were modeled (CueA, CueB, AX, AY, BX, BY) and correct responses were used to create first-level images.

Based on the exclusion criteria mentioned above, five controls, nine SZ subjects, and two BP subjects were excluded due to excess motion. Two controls, five SZ subjects, and two BP subjects were excluded for poor behavioral performance. Finally, three controls and six SZ subjects were excluded for other reasons, including scanning artifacts, scanner failure, or button pad failure.

Genotyping, quality control, and imputation

Subjects underwent blood draws using PAXgene blood DNA tubes, which were subsequently stored at −80 °C until DNA extraction. Tubes were thawed at 37 °C for 15 min before extracting DNA using the Qiagen QIAamp DNA Blood Mini Kit. The protocol was followed with minor modifications: volumes of blood, protease, lysis buffer, and ethanol were tripled prior to binding DNA to the spin column; the final elution incubation was carried out at 50 °C for 5 min; and DNA was eluted in 100 µl of nuclease-free water. DNA was cleaned on the Zymo Research Genomic DNA Clean & Concentrator-10 kit with minor modifications: an extra 2-min spin in a clean collection tube was added after completing wash steps; samples were incubated at 50 °C for 5 min during elution; and DNA was eluted in 100 µl of nuclease-free water. After cleaning, samples were analyzed on a spectrophotometer and verified to have concentrations ≥50 ng/µl and 260/280 and 260/230 ratios ≥1.70.

DNA was genotyped using the Illumina (San Diego, California) Infinium PsychArray-24 Kit at the UC Davis DNA Technologies Core. Initial QC was performed using Illumina GenomeStudio following published guidance [45, 46]. Additional QC was applied using PLINK. First, variants with greater than 5% missingness were removed. We confirmed that no individuals had more than 1% of SNPs missing, nor did we observe any mismatch between genetic sex inferred by PLINK and subjects’ self-reported sex. We removed variants with significantly different missingness rates between cases and controls (p < 0.001) or variants with significant deviation from Hardy-Weinberg equilibrium (p < 1e-6). No severe heterozygosity outliers were observed. A small number of pairs of individuals appeared to be related; in these cases one subject from each pair was randomly excluded from subsequent analyses. Following imputation, the QC filters outlined above were performed again. Additionally, variants with imputation quality INFO scores <0.7 or empirical INFO scores <0.8 were removed.

PLINK (v1.9) was used to calculate genetic principal components (PCs) in the 1000 Genomes [47] Phase 3 dataset, which were projected onto our sample. Samples were submitted to the Michigan Imputation Server for genotype imputation, using the full 1000 Genomes [47] Version 3 dataset as the reference panel. Following all QC, 7,608,150 SNPs were available across 338 unrelated subjects. Following additional review, 14 subjects with schizophreniform disorder and 2 subjects with schizotypal disorder that had initially been included were excluded from subsequent analyses due to insufficient numbers, such that the final number of subjects was 320 as described in “Study Participants.”

We additionally checked for presence of known copy number variants (CNVs) of high penetrance for schizophrenia risk in our samples using iPsychCNV5 and PennCNV [48–50], using default parameters. CNVs called by both software were retained as consensus calls for further analysis. This resulted in a total of 333 CNVs across all subjects. We cross-referenced these results with genome-wide significant CNV loci associated with SZ [51] and filtered for CNVs in our sample that overlapped with at least 50% of one of these previously identified SZ risk CNV loci. One subject with SZ appeared to have a previously described SZ risk CNV: 15q11.2 deletion. As the role of deletion at 15q11.2 is currently of uncertain significance in schizophrenia risk [52, 53], we retained this individual for all analyses.

Polygenic score calculation

Using Psychiatric Genomics Consortium GWAS summary statistics for SZ (2021) [22] and BP (2022) [54], we employed PRS-CS [55] to calculate SZ and BP PGS, with the phi parameter set to 0.01 as recommended without a validation sample. PRS-CS applies shrinkage to optimize PGS prediction and may not be applicable when restricting PGS to genes from specific pathways. Therefore, we used the PRSet function from PRSice [56] to calculate pPGS for the four neurotransmitter pathways using SZ GWAS summary statistics [22], as our subjects were weighted toward SZ diagnosis and case-control status was best described by SZ PGS. As recommended by the authors of PRSet, in order to avoid eliminating SNPs in certain genes, no p-value filter was applied when calculating pPGS. In order to select the R2 cutoff used for clumping, we tested five potential values (0.1, 0.3, 0.5, 0.7, 0.9) in the subset of European ancestry samples. All values returned a significant relationship with case-control status. For results reported here, we used a clumping R2 of 0.7 as it showed the strongest association with case status. We report results using alternative clumping values in Fig. S2, which demonstrate stability of our findings across clumping R2 values. Otherwise, default parameters of PRSet were retained, with the 1000 Genomes [47] European subset used as the LD reference panel.

To reduce bias from population stratification, we regressed calculated PGSs on the first 10 principal components of genetic variation in our subjects. We then assessed performance of regressed PGSs across different ancestries present in our study sample. Subject ancestries were estimated by assigning each subject to their nearest 1000 Genomes [47] population by minimizing Euclidean distance to population centroid in 20-dimensional PC space, as recommended by Privé et al. [57]. Regressed PGSs (hereafter called PGSs) showed substantial reduction in ancestry-specific stratification and appeared to replicate top-level associations when subsetted to just European/white subjects (Fig. S3).

pPGS pathways

Pathways include genes relevant in glutamate, GABA, dopamine, and serotonin. Genes were sourced from KEGG [58], REACTOME [59], and AmiGO [60] by searching for pathways and ontologies that include these neurotransmitters or variations on them (e.g. “glutamatergic”). The complete gene list is in Table S1.

Unbiased clustering

Endophenotypes were z-score normalized within cases. For cognitive control phenotypes, subjects were z-score normalized within cases with the same protocol/scanner type. Subjects were clustered on all endophenotypes. We used all subjects with complete endophenotype data (n = 91) to calculate the optimal number of clusters using the NbClust R package [61]. Estimates converged on three clusters. Subsequently, we used all subjects with greater than 50% of endophenotype variables available (n = 167) for k-means clustering using the flipCluster R package [62].

Statistical analysis

All analyses were completed in R [63]. Code used to generate results are available upon reasonable request to the authors. One BP subject was excluded as an outlier from analyses based on Cook’s distance near 1 in regression models. Correlation analyses and plots were produced using the psych [64] and corrplot [65] packages. Violin plots were produced using the vioplot package [66]. Effect sizes for associations are presented as standardized β coefficients and odds ratios, calculated using the lm.beta [67] R package. The center marks represent median values in the violin plots and boxplots.

Nagelkerke’s R2 was calculated for variance explained in logistic regression models of disease status by PGS using the RMS R package [68]. All endophenotypes were tested against PGS and the following covariates in regression models: chromosomal sex, age, self-reported race, self-reported ethnicity, and diagnosis. Protocol/scanner type was controlled for in cognitive control analyses. Overall SZ PGS was included as a covariate for endophenotype analyses by pPGS. Models of continuous variable phenotypes against PGS are represented with partial regression plots.

For cluster versus diagnosis model comparison, we regressed PGSs separately against clusters, plus standard covariates, and against diagnoses, plus covariates. In separate analyses, we regressed PGS against both cluster and diagnosis in the same model, as well as covariates. BP and Cluster 3 were the reference levels for, respectively, diagnosis and cluster.

Multiple testing corrections

Multiple testing corrections were applied for analyses of phenotype, including diagnosis and case status, by pathway PGS. Given the correlated structure of phenotypes and of pPGS in our subjects, we used the poolr R package [69] to calculate the effective number of statistical tests following Galwey (2009) [70]. This methodology identified effectively five (of initially six) independent PGS variables and 12 (of initially 17) independent phenotype variables. Total tested dependent variables were multiplied by total tested independent variables such that findings were corrected for 61 tests (five PGS by 12 endophenotypes plus one test for differential treatment response across k-means clusters) using a Benjamini-Hochberg [71] false discovery rate (FDR) of 0.10.

Permuted null pathway calculation

For each of the pathways in our main analyses, we constructed 10,000 matched null gene sets with an equivalent number of genes, chosen such that the probability of a gene’s inclusion is proportional to its length. We then calculated pPGS for these 40,000 permuted null gene sets in the same way as described above, i.e. using PRSet to calculate pPGS for our target sample and regressing out the first 10 genetic PCs.

Results

Demographics

Subjects were demographically heterogenous and relatively well matched across psychosis cases (n = 205) and controls (n = 115). Cases were composed of subjects with SZ, SA, and BP diagnoses (Table 1).Table 1 Demographics of study subjects.

	Cases (N)	(%)	Controls (N)	(%)	
Total	205	64%	115	36%	
Diagnosis	
  Schizophrenia	118	58%	–	–	
  Bipolar Disorder	48	23%	–	–	
  Schizoaffective Disorder	39	19%	–	–	
Race	
  African American/Black	28	14%	7	6%	
  American Indian/Alaskan Native	2	1%	0	0%	
  Asian	15	7%	27	23%	
  Caucasian/White	131	64%	61	53%	
  Native Hawaiian/Pacific Islander	3	1%	1	1%	
  Multiple or unknown	26	13%	19	17%	
Ethnicity	
  Hispanic/Latino	50	24%	17	15%	
  Non-Hispanic/Latino	151	74%	97	84%	
  Unknown	4	2%	1	1%	
Inferred 1000 Genomes superpopulation	
  African (AFR)	58	28%	19	17%	
  American (AMR)	20	10%	8	7%	
  East Asian (EAS)	14	7%	26	23%	
  European (EUR)	110	54%	53	46%	
  South Asian (SAS)	3	1%	9	8%	
Sex	
  Male	158	77%	67	58%	
  Female	47	23%	48	42%	
Mean age (s.d.)	19.7 (4.1)		19.7 (4.2)		
Study subjects were racially and ethnically diverse across both cases and controls. Potential differences in demographics were considered when controlling for covariates in subsequent analyses.

s.d. standard deviation.

Overall and pathway PGSs predict diagnostic status

We first tested whether overall PGS was associated with psychosis status, correcting for latent ancestry differences via inclusion of the top 10 PCs, as well as sex, age, and self-reported race and ethnicity. SZ PGS was associated with case status (OR = 2.69 [CI: 2.06, 3.51]; p = 1.1 × 10−4) (Fig. 1A) and explained 6.3% of variance in status (p = 1.1 × 10−4), similar to previous reports [72–76] (Fig. S1). This association was stronger in SZ (OR = 3.06 [CI: 2.26, 4.14]; p = 2.1 × 10−4) and SA (OR = 3.67 [CI: 2.32, 5.81]; p = 4.7 × 10−3) (Fig. 1B). While BP PGS was not significant in cases overall, it was elevated in BP subjects (OR = 3.55 [CI: 2.34, 5.37]; p = 2.3 × 10−3) (Fig.1A, B). These findings passed multiple testing corrections at FDR < 0.10. SZ and BP PGS were moderately correlated in SZ and SA subjects, but not BP subjects (Fig. 1C). These results were generally consistent across PGS clumping parameters (see “Methods”, Fig. S2) and when subsetting our cohort to only white European subjects (Fig. S3). Thus, overall PGS captured both transdiagnostic and diagnosis-specific genetic risk for psychotic disorders, consistent with a strong literature on partial genetic overlap between SZ, SA, and BP [6, 7, 77–79].Fig. 1 SZ and BP PGS are associated with psychotic disorder diagnoses.

A SZ PGS (top) is significantly associated with psychosis case status, while BP PGS (bottom) is not. B SZ PGS (top) is associated with SZ and SA status versus controls, but not BP status. Conversely, BP PGS (bottom) is associated with BP status versus controls, but not SZ or SA status. For each (A) and (B), the top row represents a comparison of SZ PGS across diagnostic groups, while the bottom row represents a comparison of BP PGS across diagnostic groups. C Spearman’s correlations of SZ and BP PGS in psychosis cases show moderate correlations between PGS for SZ and SA subjects, but not for BP subjects.

Association of pPGS with phenotypes

As SZ PGS had stronger overall and transdiagnostic association to psychosis in this cohort, we next tested if this risk could be further subset via pPGS associated with major neurotransmitter pathways. To dissect genetic contributions of biological pathways to clinical and neurobiological phenotypes, we calculated pPGS for loci associated with four neurotransmitter systems relevant to psychosis: glutamate [18–22], GABA [19–24], dopamine [25–28], and serotonin [28, 29], allowing overlap in genes annotated to each pathway (Fig. 2A, Table S1). These pPGS showed moderate intercorrelations and correlations with overall PGS (Fig. 2B).Fig. 2 Pathway polygenic scores (pPGS) based on four main neurotransmitter systems.

A KEGG [58], AmiGO [60], and REACTOME [59] were searched for genes associated with glutamatergic, GABAergic, dopaminergic, and serotonergic neurotransmission. B pPGS developed from these gene sets showed substantial correlation in psychosis subjects when regressing against the first ten genetic principal components. Statistically significant correlations (p < 0.05) are denoted with an asterisk. C While no pPGS significantly separated overall psychosis cases from controls, D glutamate and GABA pPGS separated SZ cases specifically from controls, though these findings do not pass FDR < 0.10.

We first tested association with overall disease status. Glutamate and GABA pPGS showed weak trends toward explaining variance in case status (OR = 1.57 [CI: 1.22, 2.04] to 1.58 [CI: 1.22, 2.05]; both p = 0.08; Fig. 2C). Glutamate and GABA pPGS showed improved explanation of SZ status over a null background distribution of size-matched gene sets (Fig. S4) and were modestly elevated in SZ subjects relative to controls (OR = 1.90 [CI: 1.42, 2.56] to 1.92 [CI: 1.43, 2.57]; both p = 0.03; Fig. 2D), though case-control separation did not pass multiple testing corrections. This suggests disease status in our cohort is partially explained by glutamatergic and GABAergic genetic risk.

pPGSs are associated with endophenotypes in cases

We next tested if PGS was associated with symptom variation across 11 phenotypes within subjects with a psychotic disorder (Fig. 3A). For these analyses, we tested for associations only within psychosis cases, as data on psychosis endophenotypes were only collected for subjects with psychosis. Overall PGSs were not significantly associated with measured phenotypes (Fig. S5). However, we found evidence for associations of pathway-specific risk to six phenotypes in global functioning, role functioning, cognitive control, and treatment response, though only DLPFC β-values by glutamate and GAF by dopamine passed multiple testing corrections at FDR < 0.10. Full data on non-significant relationships is available in Fig. S5.Fig. 3 pPGSs identify mechanisms for endophenotypes of psychotic disorders.

A Subjects were phenotyped on a range of psychological, clinical, and neurological measures. B Dopamine pPGS was associated with poorer global functioning and role functioning in psychosis subjects when controlling for diagnosis and overall SZ PGS. Only the association with global functioning passed FDR < 0.10. C Glutamate pPGS showed associations with poorer performance and reduced cortical activation in psychosis subjects during the AX-CPT cognitive control task when controlling for diagnosis and overall SZ PGS. Only the association with DLPFC β-values passed FDR < 0.10. D Treatment response showed a slight association with increased dopamine pPGS, though this did not pass FDR < 0.10. (Resp. = responder to treatment, non-resp. = non-responder to treatment).

Dopamine pPGS was associated with poorer global (β = −0.17 [CI: −0.25, −0.10]; p = 0.02) and role (β = −0.19 [CI: −0.28, −0.10]; p = 0.03) functioning, though role functioning did not pass multiple testing corrections (Fig. 3B). Perhaps the strongest finding was an association between glutamate pPGS and cognitive control in cases, though only the association to DLPFC β-values passed multiple testing corrections (DLPFC β-values: β = −0.22 [CI: −0.31, −0.13]; p = 0.01) (SPC β-values: β = −0.19 [CI: −0.29, −0.09]; p = 0.05) (d’-Context: β = −0.18 [CI: −0.26, −0.09]; p = 0.04) (Fig. 3C). This finding is consistent with a prominent hypothesis in schizophrenia literature that perturbations to glutamatergic signaling may be associated with deficits in cognitive control [80–83]. Notably, our findings represent results from a relatively small cohort and should be followed up in larger cohorts and with more detailed mechanistic studies, and only one endophenotype association to glutamate passed multiple testing corrections. However, these results show the promise of using pPGS to partition genome-wide risk into hypothesized mechanistic pathways toward symptoms of psychiatric disease.

Of 63 subjects with available treatment response data, 35 were responders, consistent with reported efficacy rates [84]. Though underpowered, treatment response showed a weak association with higher dopamine pPGS which did not pass multiple testing corrections (OR = 3.40 [CI: 1.83, 6.34]; p = 0.05) (Fig. 3D). While this finding should be considered preliminary, this is consistent with literature associating dopamine with antipsychotic efficacy.

Unbiased phenotype clustering of psychosis cases and genetic burden

Biotype-level grouping of psychosis cases, such as by B-SNIP [9], may advance the use of biological data to better model psychopathology. We hypothesized a biotype-style approach might unmask explanations of psychosis symptom heterogeneity by overall and pathway-level PGS. Toward this goal, we used k-means clustering to group endophenotype presentation among cases. We clustered subjects on z-score normalized phenotype data into three groups following cluster optimization using the NbClust R package [61].

Clusters showed distinct symptom profiles (Fig. 4A, Table S2). Cluster 1 was distinguished by high mania, disorganization, and reality distortion, and moderate impairments in cognitive control. Cluster 2 had deficits in negative symptoms, showed poor outcomes in role and social functioning, and had the poorest measures of cognitive control. Cluster 3 had low pathology. Cluster 1 showed evidence of enrichment for treatment responders relative to Clusters 2 and 3, though this did not reach significance (p = 0.057) (Fig. 4B). In contrast, treatment response showed no separation by diagnosis (p = 0.845). Clusters were demographically and diagnostically heterogenous (Fig. 4C, Table S2), though Cluster 3 captured most BP subjects. By contrast, SZ and SA subjects were relatively evenly distributed across Clusters 1 and 2. This suggests that, among endophenotypes available in our subjects, Clusters 1 and 2 captured relatively strong endophenotype differences that are transdiagnostic across SZ and SA subjects.Fig. 4 Psychosis subjects separate into clusters based on symptom profiles.

A Psychosis subjects separate into three clusters that are characterized by (Cluster 1) mania, disorganization, reality distortion, and moderate impairments in cognitive control; (Cluster 2) high poverty symptoms, poor social functioning, and strong deficits in cognitive control; and (Cluster 3) overall low levels of pathology. B Cluster 1 showed enrichment for treatment responders, though this did not pass FDR < 0.10. In contrast, treatment efficacy did not separate by diagnosis. C Diagnoses are mixed across clusters. D SZ PGS is elevated in all clusters, though this did not pass FDR < 0.10 for Cluster 3. BP PGS is elevated in Cluster 3. Glutamate and GABA pPGS are elevated in Cluster 2. E Models regressing PGS against cluster perform better for glutamate and GABA pPGS than models regressing PGS against diagnosis. Models regressing PGS by diagnosis perform better than PGS by cluster for BP PGS. Weaker evidence for performance differences by model type are present for dopamine pPGS and serotonin pPGS. F Glutamate and GABA pPGS are significantly associated with cluster membership when controlling for diagnosis. (C. 1 = Cluster 1, C. 2 = Cluster 2, C. 3 = Cluster 3, resp. = responder to treatment, non-resp. = non-responder to treatment).

We next tested associations between cluster and PGS (Fig. 4D, Table S2). SZ PGS was associated with all clusters, though this did not pass multiple testing corrections for Cluster 3 (Clust. 1: OR = 4.90 [CI: 3.01, 7.96]; p = 1.1 × 10−3) (Clust. 2: OR = 2.59 [CI: 1.83, 3.66]; p = 6.1 × 10−3) (Clust. 3: OR = 2.21 [CI: 1.53, 3.19]; p = 0.03). BP PGS was strongly associated with Cluster 3 (OR = 2.51 [CI: 1.74, 3.60]; p = 0.01), consistent with its preponderance of BP subjects. Cluster 3 was not associated with any pPGS, suggesting genetic risk may lie outside of SZ variants in neurotransmitter-linked loci. In contrast, GABA (OR = 2.51 [CI: 1.78, 3.53]; p = 0.01) and glutamate (OR = 3.21 [CI: 2.24, 4.59]; p = 1.15 × 10−3) pPGS were elevated in Cluster 2, both of which passed multiple testing corrections. This may have implications for the symptom profiles of this cluster. Cluster 2 showed strong negative symptoms, which are thought to largely arise from glutamatergic dysfunction [85, 86]. Cluster 2 also showed deficits in social and role functioning, which are predicted by negative symptoms [87], and strong cognitive control deficits. pPGS findings suggest Cluster 2’s symptoms in our cohort may be more specific to GABAergic and glutamatergic risk, consistent with the hypothesis of an imbalance between these neurotransmitters in psychosis [20]. Following up on these findings in larger cohorts may eventually prove useful in identifying pathways underlying transdiagnostic psychiatric symptoms.

We next compared explanatory power of our clusters versus diagnoses to model genetic risk in our cohort. For this, we defined models regressing PGSs against either cluster or diagnosis. Per Bayesian information criteria and R2 (Fig. 4E), models using clusters performed better than models using diagnosis to predict, in particular, glutamatergic and GABAergic pPGS. We next regressed PGS against both cluster and diagnosis as covariates to test independence between diagnosis and cluster (Fig. 4F). Again, glutamate (β = 0.23 [CI: 0.14, 0.33]; p = 0.02) and GABA (β = 0.20 [CI: 0.10, 0.29]; p = 0.04) pPGS were associated with Cluster 2 when including diagnosis in the model. These results demonstrate that, within subjects of the same diagnosis, endophenotypes captured here showed specific associations to glutamatergic and GABAergic pPGS. These results provide evidence for the biological validity of these clusters overall within our cohort and within the context of molecular pathways.

Discussion

We tested how overall and pathway-specific PGS are related to diagnosis and variation in psychosis symptoms in a diverse patient sample. We calculated overall SZ and BP PGS, and further curated gene sets representing four major neurotransmitter systems [58–60], comparing pPGS for SZ variants in these pathways. Overall genome-wide PGS, and to a weaker degree glutamate and GABA pPGS, were associated with case status, though glutamate and GABA did not pass multiple testing corrections. pPGSs outperformed overall PGS in explaining endophenotypes. Dopamine was significantly associated with poorer overall functioning and marginally associated with treatment response, though the association to treatment response did not pass multiple testing corrections. This is a preliminary but intriguing result, suggesting the hypothesis for future research that patients with increased dopaminergic risk may be better candidates for antipsychotic medications. Our results also showed associations between glutamate pPGS and cognitive control. Unsupervised clustering identified three phenotypically distinct groups of psychosis subjects that differed predominantly on positive symptoms, negative symptoms, cognitive control, and global functioning. Though our data largely represent different phenotypic measurements than those used by B-SNIP, we reproduced those findings which our measures can capture and generated preliminary hypotheses on the relationship between biotypes and genetic burden. Like B-SNIP, we identified three diagnostically mixed endophenotypes in our subjects that separate on general impairment and cognitive control. Notably, Cluster 2, which showed primary deficits in cognitive control, negative symptoms, and social functioning, had elevated glutamatergic and GABAergic risk. Treatment efficacy showed some evidence for separation by cluster. Within diagnoses, clustering on available endophenotypes unmasked different symptom presentations that showed specific profiles of genetic risk. Our results require replication before generalization outside of our small cohort, but may serve as proof-of-principle for the use of biologically partitioned polygenic risk to study shared mechanisms behind psychiatric symptoms.

Our study features limitations. Notably, our cohort is smaller than many genomics studies, though our deep level of phenotyping is a strength and generally not possible for the larger or combined cohorts needed for GWAS. As a result of our small sample, our results should be considered preliminary data and are best understood as a model for the use of pPGS to study hypothesized mechanisms of disease. Additional cohorts featuring endophenotypes not captured in our study, such as mood symptoms or potential biomarkers of disease, may help draw a more complete picture of how genetic burden drives psychiatric symptomatology. Focusing on PGS rather than SNP discovery mitigates the limitations of our sample size, though limits our study to integration of previously defined associations. We tested a priori-defined and hypothesis-driven pathways in the present study, however, there are certain to be other contributing pathways not investigated here. While diverse cohorts are needed to capture generalized genetic risk across populations, there is currently no standard for transposing PGS across ancestries. Here, we regressed PGS on the first 10 genetic PCs and additionally controlled for race and ancestry in association analyses and show that our methods generally address ancestry differences in PGS in our cohort. However, future studies on larger diverse replication cohorts will be needed. Finally, k-means clustering will identify clusters even when the true nature of the data is continuous or cluster differences are not biologically relevant. The identification of unique PGS profiles for our clusters, as well as evidence for by-cluster differences in treatment response, provide auxiliary evidence supporting separate mechanisms driving distinct clusters of primary symptoms within our subjects. PGSs showed associations to specific clusters even within subjects of the same diagnosis. Additionally, we replicate key findings from previous clustering attempts on psychosis subjects [9].

Our results show the utility of overall and pathway-specific PGS to understand genetic burden and interrogate convergent neurobiological mechanisms underlying disease phenotypes. The neurotransmitter systems tested here have been robustly associated with psychotic disorders [18–29]. However, their relationships to specific symptoms have not been elucidated. Mechanisms underlying cognitive and negative symptoms in psychosis are particularly poorly understood, despite being some of the strongest predictors of poor outcomes in psychotic disorders [88–91]. Our results support a role for glutamate dysfunction in cognitive, as well as negative and social, symptoms in psychosis. This adds to a wide literature hypothesizing that the biological basis of these symptoms may be partly explained by genetic risk driving glutamatergic abnormalities. Our study and findings represent a model for going beyond overall genetic burden in investigation of the genetic components of psychosis, and, in particular, of maximizing power in smaller but deeply characterized cohorts. While our findings will need to be replicated, they offer a promising look into how genetic burden can be partitioned and can explain specific psychosis diagnoses and endophenotypes. Our work is a step towards a more precise understanding of convergent molecular mechanisms underlying psychotic symptoms, which is critical for realizing the promise of stratified medicine and targeted treatments for those suffering from psychotic disorders.

Supplementary information

Supplementary figures and tables

Supplementary table S1

Data file

Supplementary information

The online version contains supplementary material available at 10.1038/s41380-024-02457-0.

Acknowledgements

Subject recruitment, blood draws, and phenotyping were supported by NIMH grant R01MH059883. DNA extraction and genotyping were supported by the UC Davis-HKU Collaboration Grant. Analyses and writing were supported by the UC Davis LaMP T32 (NIMH T32MH112507), the NIMH NRSA F31MH129135, and NIGMS grant R35GM119831.

Author contributions

TLW and JDT contributed equally to this research. TLW, JDT, TAL, CSC, PCS, and ASN contributed to overall study concept and design. TAL, CSC, SSP, MDA, PS, and VZ contributed to subject recruitment and phenotypic data acquisition and analysis. TLW, MBC, and SJM contributed to genetic data acquisition. JDT and PCS contributed to cleaning and analysis of genetic data and calculating polygenic scores and principal components of variation. TW and ASN contributed to analyses of relationships between phenotypic and genetic data. TW, JDT, and TAL contributed to manuscript writing. All authors contributed to critical evaluation of methods and content, and to editing of the manuscript. CSC, PCS, and ASN jointly supervised this research.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Tracy L. Warren, Justin D. Tubbs.
==== Refs
References

1. Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS ONE. 2018;13:e0195687.
2. van Os J Hanssen M Bijl RV Vollebergh W Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison Arch Gen Psychiatry 2001 58 663 10.1001/archpsyc.58.7.663 11448373
van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry. 2001;58:663.11448373
3. Subramaniam M Abdin E Vaingankar JA Sambasivam R Zhang YJ Shafie S Lifetime prevalence and correlates of schizophrenia and other psychotic disorders in Singapore Front Psychiatry 2021 12 650674 10.3389/fpsyt.2021.650674 33776823
Subramaniam M, Abdin E, Vaingankar JA, Sambasivam R, Zhang YJ, Shafie S, et al. Lifetime prevalence and correlates of schizophrenia and other psychotic disorders in Singapore. Front Psychiatry. 2021;12:650674.33776823
4. Sharifi V, Amin-Esmaeili M, Hajebi A, Motevalian A, Radgoodarzi R, Hefazi M, et al. Twelve-month prevalence and correlates of psychiatric disorders in Iran: the Iranian Mental Health Survey, 2011. Arch Iran Med. 2015;18:76–84.
5. Phillips MR Zhang J Shi Q Song Z Ding Z Pang S Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey Lancet 2009 373 2041 53 10.1016/S0140-6736(09)60660-7 19524780
Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009;373:2041–53.19524780
6. Lee PH Anttila V Won H Feng YCA Rosenthal J Zhu Z Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders Cell. 2019 179 1469 1482.e11 10.1016/j.cell.2019.11.020 31835028
Lee PH, Anttila V, Won H, Feng YCA, Rosenthal J, Zhu Z, et al. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell. 2019;179:1469–1482.e11.31835028
7. Lee PH Feng YCA Smoller JW Pleiotropy and cross-disorder genetics among psychiatric disorders Biol Psychiatry 2021 89 20 31 10.1016/j.biopsych.2020.09.026 33131714
Lee PH, Feng YCA, Smoller JW. Pleiotropy and cross-disorder genetics among psychiatric disorders. Biol Psychiatry. 2021;89:20–31.33131714
8. Light G Greenwood TA Swerdlow NR Calkins ME Freedman R Green MF Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study Schizophr Bull 2014 40 1404 11 10.1093/schbul/sbu064 24903414
Light G, Greenwood TA, Swerdlow NR, Calkins ME, Freedman R, Green MF, et al. Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study. Schizophr Bull. 2014;40:1404–11.24903414
9. Clementz BA Sweeney JA Hamm JP Ivleva EI Ethridge LE Pearlson GD Identification of distinct psychosis biotypes using brain-based biomarkers Am J Psychiatry 2016 173 373 84 10.1176/appi.ajp.2015.14091200 26651391
Clementz BA, Sweeney JA, Hamm JP, Ivleva EI, Ethridge LE, Pearlson GD, et al. Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry. 2016;173:373–84.26651391
10. Zhang JP Robinson D Yu J Gallego J Fleischhacker WW Kahn RS Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis Am J Psychiatry 2019 176 21 8 10.1176/appi.ajp.2018.17121363 30392411
Zhang JP, Robinson D, Yu J, Gallego J, Fleischhacker WW, Kahn RS, et al. Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis. Am J Psychiatry. 2019;176:21–8.30392411
11. Shafee R Nanda P Padmanabhan JL Tandon N Alliey-Rodriguez N Kalapurakkel S Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls Transl Psychiatry 2018 8 78 10.1038/s41398-018-0124-8 29643358
Shafee R, Nanda P, Padmanabhan JL, Tandon N, Alliey-Rodriguez N, Kalapurakkel S, et al. Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. Transl Psychiatry. 2018;8:78.29643358
12. He Q Jantac Mam-Lam-Fook C Chaignaud J Danset-Alexandre C Iftimovici A Gradels Hauguel J Influence of polygenic risk scores for schizophrenia and resilience on the cognition of individuals at-risk for psychosis Transl Psychiatry 2021 11 518 10.1038/s41398-021-01624-z 34628483
He Q, Jantac Mam-Lam-Fook C, Chaignaud J, Danset-Alexandre C, Iftimovici A, Gradels Hauguel J, et al. Influence of polygenic risk scores for schizophrenia and resilience on the cognition of individuals at-risk for psychosis. Transl Psychiatry. 2021;11:518.34628483
13. Choi SW García-González J Ruan Y Wu HM Porras C Johnson J PRSet: pathway-based polygenic risk score analyses and software PLoS Genet 2023 19 e1010624 10.1371/journal.pgen.1010624 36749789
Choi SW, García-González J, Ruan Y, Wu HM, Porras C, Johnson J, et al. PRSet: pathway-based polygenic risk score analyses and software. PLoS Genet. 2023;19:e1010624.36749789
14. Yao Y Guo W Zhang S Yu H Yan H Zhang H Cell type-specific and cross-population polygenic risk score analyses of MIR137 gene pathway in schizophrenia iScience 2021 24 102785 10.1016/j.isci.2021.102785 34308291
Yao Y, Guo W, Zhang S, Yu H, Yan H, Zhang H, et al. Cell type-specific and cross-population polygenic risk score analyses of MIR137 gene pathway in schizophrenia. iScience. 2021;24:102785.34308291
15. Cosgrove D Harold D Mothersill O Anney R Hill MJ Bray NJ MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls Transl Psychiatry 2017 7 e1012 10.1038/tp.2016.286 28117840
Cosgrove D, Harold D, Mothersill O, Anney R, Hill MJ, Bray NJ, et al. MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls. Transl Psychiatry. 2017;7:e1012.28117840
16. Cosgrove D Mothersill DO Whitton L Harold D Kelly S Holleran L Effects of MiR-137 genetic risk score on brain volume and cortical measures in patients with schizophrenia and controls Am J Med Genet B Neuropsychiatr Genet 2018 177 369 76 10.1002/ajmg.b.32620 29418072
Cosgrove D, Mothersill DO, Whitton L, Harold D, Kelly S, Holleran L, et al. Effects of MiR-137 genetic risk score on brain volume and cortical measures in patients with schizophrenia and controls. Am J Med Genet B Neuropsychiatr Genet. 2018;177:369–76.29418072
17. Reay WR Geaghan MP Atkins JR Carr VJ Green MJ Cairns MJ Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder Am J Hum Genet 2022 109 1620 37 10.1016/j.ajhg.2022.07.011 36055211
Reay WR, Geaghan MP, Atkins JR, Carr VJ, Green MJ, Cairns MJ. Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder. Am J Hum Genet. 2022;109:1620–37.36055211
18. Ohi K Hashimoto R Ikeda M Yamamori H Yasuda Y Fujimoto M Glutamate networks implicate cognitive impairments in schizophrenia: genome-wide association studies of 52 cognitive phenotypes Schizophr Bull 2015 41 909 18 10.1093/schbul/sbu171 25537281
Ohi K, Hashimoto R, Ikeda M, Yamamori H, Yasuda Y, Fujimoto M, et al. Glutamate networks implicate cognitive impairments in schizophrenia: genome-wide association studies of 52 cognitive phenotypes. Schizophr Bull. 2015;41:909–18.25537281
19. Fromer M Roussos P Sieberts SK Johnson JS Kavanagh DH Perumal TM Gene expression elucidates functional impact of polygenic risk for schizophrenia Nat Neurosci 2016 19 1442 53 10.1038/nn.4399 27668389
Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci. 2016;19:1442–53.27668389
20. Koshiyama D Kirihara K Tada M Nagai T Fujioka M Ichikawa E Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset Transl Psychiatry 2018 8 211 10.1038/s41398-018-0261-0 30297786
Koshiyama D, Kirihara K, Tada M, Nagai T, Fujioka M, Ichikawa E, et al. Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset. Transl Psychiatry. 2018;8:211.30297786
21. Reddy-Thootkur M Kraguljac NV Lahti AC The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders – A systematic review of magnetic resonance spectroscopy studies Schizophr Res 2022 249 74 84 10.1016/j.schres.2020.02.001 32107102
Reddy-Thootkur M, Kraguljac NV, Lahti AC. The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders – A systematic review of magnetic resonance spectroscopy studies. Schizophr Res. 2022;249:74–84.32107102
22. Trubetskoy V Pardiñas AF Qi T Panagiotaropoulou G Awasthi S Bigdeli TB Mapping genomic loci implicates genes and synaptic biology in schizophrenia Nature 2022 604 502 8 10.1038/s41586-022-04434-5 35396580
Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 2022;604:502–8.35396580
23. Devor A Andreassen OA Wang Y Mäki-Marttunen T Smeland OB Fan CC Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia Mol Psychiatry 2017 22 792 801 10.1038/mp.2017.33 28348379
Devor A, Andreassen OA, Wang Y, Mäki-Marttunen T, Smeland OB, Fan CC, et al. Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia. Mol Psychiatry. 2017;22:792–801.28348379
24. Karolinska Schizophrenia Project (KaSP) ConsortiumOrhan F Fatouros-Bergman H Goiny M Malmqvist A Piehl F CSF GABA is reduced in first-episode psychosis and associates to symptom severity Mol Psychiatry 2018 23 1244 50 10.1038/mp.2017.25 28289277
Karolinska Schizophrenia Project (KaSP) Consortium, Orhan F, Fatouros-Bergman H, Goiny M, Malmqvist A, Piehl F, et al. CSF GABA is reduced in first-episode psychosis and associates to symptom severity. Mol Psychiatry. 2018;23:1244–50.28289277
25. Seeman P Chau-Wong M Tedesco J Wong K Brain receptors for antipsychotic drugs and dopamine: direct binding assays Proc Natl Acad Sci USA 1975 72 4376 80 10.1073/pnas.72.11.4376 1060115
Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA. 1975;72:4376–80.1060115
26. Creese I Burt DR Snyder SH Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science. 1976 192 481 3 10.1126/science.3854 3854
Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481–3.3854
27. Seeman P Schwarz J Chen JF Szechtman H Perreault M McKnight GS Psychosis pathways converge via D2High dopamine receptors Synapse. 2006 60 319 46 10.1002/syn.20303 16786561
Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, et al. Psychosis pathways converge via D2High dopamine receptors. Synapse. 2006;60:319–46.16786561
28. Richtand NM Welge JA Logue AD Keck PE Strakowski SM McNamara RK Dopamine and serotonin receptor binding and antipsychotic efficacy Neuropsychopharmacology. 2007 32 1715 26 10.1038/sj.npp.1301305 17251913
Richtand NM, Welge JA, Logue AD, Keck PE, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology. 2007;32:1715–26.17251913
29. Baou M Boumba VA Petrikis P Rallis G Vougiouklakis T Mavreas V A review of genetic alterations in the serotonin pathway and their correlation with psychotic diseases and response to atypical antipsychotics Schizophr Res 2016 170 18 29 10.1016/j.schres.2015.11.003 26644303
Baou M, Boumba VA, Petrikis P, Rallis G, Vougiouklakis T, Mavreas V. A review of genetic alterations in the serotonin pathway and their correlation with psychotic diseases and response to atypical antipsychotics. Schizophr Res. 2016;170:18–29.26644303
30. First M, Spitzer R, Gibbon M, Williams J. Structured clinical interview for DSM-IV-TR axis I disorders, research version, Patient Edition. (SCID-I/P). In: Biometrics research. New York: New York State Psychiatric Institute; 2002.
31. American Psychiatric Association. Global assessment of functioning (GAF). In: Diagnostic and statistical manual on mental disorders, third ed text rev. Washington, DC: American Psychiatric Association; 1987.
32. Auther A, Smith C, Cornblatt B. Global functioning: social scale (GF: Social). Glen Oaks, New York: Zucker-Hillside Hospital; 2006.
33. Niendam T, Bearden C, Johnson J, Cannon T. Global functioning: role scale (GF: Role). Los Angeles: University of California, Los Angeles; 2006.
34. Young RC Biggs JT Ziegler VE Meyer DA A rating scale for mania: reliability, validity and sensitivity Br J Psychiatry 1978 133 429 35 10.1192/bjp.133.5.429 728692
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.728692
35. Andreasen NC. The scales of negative (SANS) and positive (SAPS) symptoms. Iowa City: University of Iowa; 1984.
36. Overall JE Gorham DR The brief psychiatric rating scale Psychol Rep 1962 10 799 812 10.2466/pr0.1962.10.3.799
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
37. Barch DM Carter CS MacDonald AW Braver TS Cohen JD Context-processing deficits in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms J Abnorm Psychol 2003 112 132 43 10.1037/0021-843X.112.1.132 12653421
Barch DM, Carter CS, MacDonald AW, Braver TS, Cohen JD. Context-processing deficits in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms. J Abnorm Psychol. 2003;112:132–43.12653421
38. Howes OD Bose SK Turkheimer F Valli I Egerton A Valmaggia LR Dopamine synthesis capacity before onset of psychosis: a prospective [18 F]-DOPA PET imaging study Am J Psychiatry 2011 168 1311 7 10.1176/appi.ajp.2011.11010160 21768612
Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18 F]-DOPA PET imaging study. Am J Psychiatry. 2011;168:1311–7.21768612
39. Howes OD McCutcheon R Agid O de Bartolomeis A van Beveren NJM Birnbaum ML Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology Am J Psychiatry 2017 174 216 29 10.1176/appi.ajp.2016.16050503 27919182
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216–29.27919182
40. Smucny J Lesh TA Carter CS Baseline frontoparietal task-related BOLD activity as a predictor of improvement in clinical symptoms at 1-year follow-up in recent-onset psychosis Am J Psychiatry 2019 176 839 45 10.1176/appi.ajp.2019.18101126 31256610
Smucny J, Lesh TA, Carter CS. Baseline frontoparietal task-related BOLD activity as a predictor of improvement in clinical symptoms at 1-year follow-up in recent-onset psychosis. Am J Psychiatry. 2019;176:839–45.31256610
41. Rosvold HE Mirsky AF Sarason I Bransome ED Beck LH A continuous performance test of brain damage J Consult Psychol 1956 20 343 50 10.1037/h0043220 13367264
Rosvold HE, Mirsky AF, Sarason I, Bransome ED, Beck LH. A continuous performance test of brain damage. J Consult Psychol. 1956;20:343–50.13367264
42. Henderson D Poppe AB Barch DM Carter CS Gold JM Ragland JD Optimization of a goal maintenance task for use in clinical applications Schizophr Bull 2012 38 104 13 10.1093/schbul/sbr172 22199092
Henderson D, Poppe AB, Barch DM, Carter CS, Gold JM, Ragland JD, et al. Optimization of a goal maintenance task for use in clinical applications. Schizophr Bull. 2012;38:104–13.22199092
43. Minzenberg MJ Laird AR Thelen S Carter CS Glahn DC Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia Arch Gen Psychiatry 2009 66 811 10.1001/archgenpsychiatry.2009.91 19652121
Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 2009;66:811.19652121
44. MacDonald AW Cohen JD Stenger VA Carter CS Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control Science 2000 288 1835 8 10.1126/science.288.5472.1835 10846167
MacDonald AW, Cohen JD, Stenger VA, Carter CS. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science. 2000;288:1835–8.10846167
45. Infinium® Genotyping Data Analysis: a guide for analyzing Infinium genotyping data using the GenomeStudio® Genotyping Module. https://pre.illumina.com.cn/content/dam/illumina-marketing/documents/products/technotes/technote_infinium_genotyping_data_analysis.pdf.
46. Patel H, Hyuck Sang L. GenomeStudio Genotyping QC SOP v.1.6. https://khp-informatics.github.io/COPILOT/GenomeStudio_genotyping_SOP.html.
47. Siva N 1000 Genomes project Nat Biotechnol 2008 26 256 10.1038/nbt0308-256b 18327223
Siva N. 1000 Genomes project. Nat Biotechnol. 2008;26:256.18327223
48. Wang K Li M Hadley D Liu R Glessner J Grant SFA PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data Genome Res 2007 17 1665 74 10.1101/gr.6861907 17921354
Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SFA, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007;17:1665–74.17921354
49. Diskin SJ Li M Hou C Yang S Glessner J Hakonarson H Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms Nucleic Acids Res 2008 36 e126 10.1093/nar/gkn556 18784189
Diskin SJ, Li M, Hou C, Yang S, Glessner J, Hakonarson H, et al. Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res. 2008;36:e126.18784189
50. Wang K Chen Z Tadesse MG Glessner J Grant SFA Hakonarson H Modeling genetic inheritance of copy number variations Nucleic Acids Res 2008 36 e138 10.1093/nar/gkn641 18832372
Wang K, Chen Z, Tadesse MG, Glessner J, Grant SFA, Hakonarson H, et al. Modeling genetic inheritance of copy number variations. Nucleic Acids Res. 2008;36:e138.18832372
51. Rees E Walters JTR Georgieva L Isles AR Chambert KD Richards AL Analysis of copy number variations at 15 schizophrenia-associated loci Br J Psychiatry 2014 204 108 14 10.1192/bjp.bp.113.131052 24311552
Rees E, Walters JTR, Georgieva L, Isles AR, Chambert KD, Richards AL, et al. Analysis of copy number variations at 15 schizophrenia-associated loci. Br J Psychiatry. 2014;204:108–14.24311552
52. Grozeva D Conrad DF Barnes CP Hurles M Owen MJ O’Donovan MC Independent estimation of the frequency of rare CNVs in the UK population confirms their role in schizophrenia Schizophr Res 2012 135 1 7 10.1016/j.schres.2011.11.004 22130109
Grozeva D, Conrad DF, Barnes CP, Hurles M, Owen MJ, O’Donovan MC, et al. Independent estimation of the frequency of rare CNVs in the UK population confirms their role in schizophrenia. Schizophr Res. 2012;135:1–7.22130109
53. Levinson DF Duan J Oh S Wang K Sanders AR Shi J Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications Am J Psychiatry 2011 168 302 16 10.1176/appi.ajp.2010.10060876 21285140
Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, et al. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry. 2011;168:302–16.21285140
54. Mullins N Forstner AJ O’Connell KS Coombes B Coleman JRI Qiao Z Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology Nat Genet 2021 536 17817 29
Mullins N, Forstner AJ, O’Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;536:17817–29.
55. Ge T Chen CY Ni Y Feng YCA Smoller JW Polygenic prediction via Bayesian regression and continuous shrinkage priors Nat Commun 2019 10 1776 10.1038/s41467-019-09718-5 30992449
Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10:1776.30992449
56. Choi SW O’Reilly PF PRSice-2: Polygenic Risk Score software for biobank-scale data GigaScience 2019 8 giz082 10.1093/gigascience/giz082 31307061
Choi SW, O’Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. GigaScience 2019;8:giz082.31307061
57. Privé F Aschard H Carmi S Folkersen L Hoggart C O’Reilly PF Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort Am J Hum Genet 2022 109 12 23 10.1016/j.ajhg.2021.11.008 34995502
Privé F, Aschard H, Carmi S, Folkersen L, Hoggart C, O’Reilly PF, et al. Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. Am J Hum Genet. 2022;109:12–23.34995502
58. Ogata H Goto S Sato K Fujibuchi W Bono H Kanehisa M KEGG: Kyoto encyclopedia of genes and genomes Nucleic Acids Res 1999 27 29 34 10.1093/nar/27.1.29 9847135
Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999;27:29–34.9847135
59. Joshi-Tope G Reactome: a knowledgebase of biological pathways Nucleic Acids Res. 2004 33 D428 32 10.1093/nar/gki072
Joshi-Tope G. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2004;33:D428–32.
60. Carbon S Ireland A Mungall CJ Shu S Marshall B Lewis S AmiGO: online access to ontology and annotation data Bioinformatics 2009 25 288 9 10.1093/bioinformatics/btn615 19033274
Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S, et al. AmiGO: online access to ontology and annotation data. Bioinformatics 2009;25:288–9.19033274
61. Charrad M, Ghazzali N, Boiteau V, Niknafs A. NbClust: an R package for determining the relevant number of clusters in a data set. J Stat Softw. 2014. http://www.jstatsoft.org/v61/i06/.
62. DisplayR. flipCluster: Cluster analysis. R package version 1.1.11 2023. https://rdrr.io/github/Displayr/flipCluster/.
63. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. https://www.R-project.org/.
64. Revelle W. psych: Procedures for psychological, psychometric, and personality research. Evanston, Illinois: Northwestern University; 2022. https://CRAN.R-project.org/package=psych.
65. Wei T, Simko V. R package “corrplot”: Visualization of a Correlation Matrix. 2021. https://github.com/taiyun/corrplot.
66. Adler D, Kelly ST, Elliot T, Adamson J. vioplot: violin plot. 2022. https://github.com/TomKellyGenetics/vioplot.
67. Behrendt S. lm.beta: add standardized regression coefficients to linear-model-objects. 2023. https://CRAN.R-project.org/package=lm.beta.
68. Harrell FE. rms: Regression modeling strategies. 2023. https://CRAN.R-project.org/package=rms.
69. Cinar O, Viechtbauer W. The poolr package for combining independent and dependent p values. J Stat Softw. 2022. https://www.jstatsoft.org/v101/i01/
70. Galwey NW A new measure of the effective number of tests, a practical tool for comparing families of non-independent significance tests Genet Epidemiol 2009 33 559 68 10.1002/gepi.20408 19217024
Galwey NW. A new measure of the effective number of tests, a practical tool for comparing families of non-independent significance tests. Genet Epidemiol. 2009;33:559–68.19217024
71. Benjamini Y Hochberg Y Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc Ser B Methodol 1995 57 289 300 10.1111/j.2517-6161.1995.tb02031.x
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289–300.
72. Perkins DO Olde Loohuis L Barbee J Ford J Jeffries CD Addington J Polygenic risk score contribution to psychosis prediction in a target population of persons at clinical high risk Am J Psychiatry 2020 177 155 63 10.1176/appi.ajp.2019.18060721 31711302
Perkins DO, Olde Loohuis L, Barbee J, Ford J, Jeffries CD, Addington J, et al. Polygenic risk score contribution to psychosis prediction in a target population of persons at clinical high risk. Am J Psychiatry. 2020;177:155–63.31711302
73. Calafato MS Thygesen JH Ranlund S Zartaloudi E Cahn W Crespo-Facorro B Use of schizophrenia and bipolar disorder polygenic risk scores to identify psychotic disorders Br J Psychiatry 2018 213 535 41 10.1192/bjp.2018.89 30113282
Calafato MS, Thygesen JH, Ranlund S, Zartaloudi E, Cahn W, Crespo-Facorro B, et al. Use of schizophrenia and bipolar disorder polygenic risk scores to identify psychotic disorders. Br J Psychiatry. 2018;213:535–41.30113282
74. Smigielski L Papiol S Theodoridou A Heekeren K Gerstenberg M Wotruba D Polygenic risk scores across the extended psychosis spectrum Transl Psychiatry 2021 11 600 10.1038/s41398-021-01720-0 34836939
Smigielski L, Papiol S, Theodoridou A, Heekeren K, Gerstenberg M, Wotruba D, et al. Polygenic risk scores across the extended psychosis spectrum. Transl Psychiatry. 2021;11:600.34836939
75. Vassos E Di Forti M Coleman J Iyegbe C Prata D Euesden J An examination of polygenic score risk prediction in individuals with first-episode psychosis Biol Psychiatry 2017 81 470 7 10.1016/j.biopsych.2016.06.028 27765268
Vassos E, Di Forti M, Coleman J, Iyegbe C, Prata D, Euesden J, et al. An examination of polygenic score risk prediction in individuals with first-episode psychosis. Biol Psychiatry. 2017;81:470–7.27765268
76. Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.
77. Cardno AG Owen MJ Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder Schizophr Bull 2014 40 504 15 10.1093/schbul/sbu016 24567502
Cardno AG, Owen MJ. Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder. Schizophr Bull. 2014;40:504–15.24567502
78. ReproGen Consortium, Psychiatric Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3, Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47:1236–41.
79. Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, Pavlides JMW, et al. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell. 2018;173:1705–15.e16.
80. Morgenroth E Orlov N Lythgoe DJ Stone JM Barker H Munro J Altered relationship between prefrontal glutamate and activation during cognitive control in people with high trait anxiety Cortex J Devoted Study Nerv Syst Behav 2019 117 53 63 10.1016/j.cortex.2019.02.021
Morgenroth E, Orlov N, Lythgoe DJ, Stone JM, Barker H, Munro J, et al. Altered relationship between prefrontal glutamate and activation during cognitive control in people with high trait anxiety. Cortex J Devoted Study Nerv Syst Behav. 2019;117:53–63.
81. Falkenberg LE Westerhausen R Craven AR Johnsen E Kroken RA L Berg EM Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia NeuroImage Clin 2014 4 576 84 10.1016/j.nicl.2014.03.014 24749064
Falkenberg LE, Westerhausen R, Craven AR, Johnsen E, Kroken RA, L Berg EM, et al. Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia. NeuroImage Clin. 2014;4:576–84.24749064
82. Falkenberg LE Westerhausen R Specht K Hugdahl K Resting-state glutamate level in the anterior cingulate predicts blood-oxygen level-dependent response to cognitive control Proc Natl Acad Sci USA 2012 109 5069 73 10.1073/pnas.1115628109 22411802
Falkenberg LE, Westerhausen R, Specht K, Hugdahl K. Resting-state glutamate level in the anterior cingulate predicts blood-oxygen level-dependent response to cognitive control. Proc Natl Acad Sci USA. 2012;109:5069–73.22411802
83. Bustillo JR Chen H Gasparovic C Mullins P Caprihan A Qualls C Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla Biol Psychiatry 2011 69 19 27 10.1016/j.biopsych.2010.08.024 20970118
Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry. 2011;69:19–27.20970118
84. Leucht S Leucht C Huhn M Chaimani A Mavridis D Helfer B Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors Am J Psychiatry 2017 174 927 42 10.1176/appi.ajp.2017.16121358 28541090
Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927–42.28541090
85. Goff DC Coyle JT The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am J Psychiatry 2001 158 1367 77 10.1176/appi.ajp.158.9.1367 11532718
Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158:1367–77.11532718
86. Gruber O, Chadha Santuccione A, Aach H. Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psychiatry. 2014. http://journal.frontiersin.org/article/10.3389/fpsyt.2014.00032/abstract.
87. Ereshefsky S Zarubin V Tryon V Lesh T Carter C Niendam T T76. Retrospective adhd symptoms in early psychosis: relation to current clinical symptoms and psychosocial functioning Schizophr Bull 2020 46 S260 1 10.1093/schbul/sbaa029.636
Ereshefsky S, Zarubin V, Tryon V, Lesh T, Carter C, Niendam T. T76. Retrospective adhd symptoms in early psychosis: relation to current clinical symptoms and psychosocial functioning. Schizophr Bull. 2020;46:S260–1.
88. Bow-Thomas CC Velligan DI Miller AL Olsen J Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization Psychiatry Res 1999 86 131 42 10.1016/S0165-1781(99)00023-2 10397415
Bow-Thomas CC, Velligan DI, Miller AL, Olsen J. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res. 1999;86:131–42.10397415
89. Dickerson F Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up Schizophr Res 1999 37 13 20 10.1016/S0920-9964(98)00134-0 10227104
Dickerson F. Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. Schizophr Res. 1999;37:13–20.10227104
90. Bowie CR Reichenberg A Patterson TL Heaton RK Harvey PD Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms Am J Psychiatry 2006 163 418 25 10.1176/appi.ajp.163.3.418 16513862
Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006;163:418–25.16513862
91. Green MF Kern RS Braff DL Mintz J Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “Right Stuff”? Schizophr Bull 2000 26 119 36 10.1093/oxfordjournals.schbul.a033430 10755673
Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “Right Stuff”? Schizophr Bull. 2000;26:119–36.10755673
